Delhi HC Issues Notice on Contempt Plea filed by ANI Media Private Limited || Rights of Mutation: Del. HC Initiates Suo Motu PIL Over Lack of Policies for Mutation of Property || All. HC: Can’t Implicate Co-Accused u/s 149 when there is No Meeting of Mind Regarding Common Object || SC: Factum of Causing Injury Not Relevant When Accused Roped in as Member of Unlawful Assembly || Meghalaya Govt. to SC: Circular Issued Regarding Prohibition of 'Two Finger test' on Rape Survivors || SC: No Minimum Sentence Prescribed for Conviction Under Section 304(A) and 338 of IPC || Kar. HC: Offence Under Widlife Protection Act Shouldn’t be Kept Pending for Very Long || Mad. HC: Courts Have Power to Grant Maintenance to Muslim Woman Who Has Filed for Divorce || Bom. HC: Bail Granted to Man on Ground of Having No Intention to Disrupt Public Peace || MP HC: Transferring Accused Merely Because ICC Proceedings are Pending is Unjustified

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :